Upcoming Data Determines Direction

$NASDAQ:ADXS could have an interesting week ahead of it right now. Not only is it back at a clear level of support/resistance, the company has data to digest:

Despite the last few months of selling pressure, the last few weeks showed a bit more bullish momentum. In fact, ADXS stock jumped to highs of $0.7597 after releasing updated data from the ADXS-503 combination study with KEYTRUDA®. Ken Berlin, Chief Executive Officer of Advaxis, explained, “The clinical activity observed to date in this challenging patient population, combined with a favorable safety profile, suggest that ADXS-503 may be an important new off-the-shelf immunotherapy treatment option. We look forward to continued progress in the clinic with our ADXS-HOT products, which includes the ongoing Phase 1/2 study of ADXS-503 in NSCLC, and the expansion of the program to our planned Phase 1 Study of ADXS-504 for the treatment of early prostate cancer.” More details will be presented as a poster at the ASCO 2021 Annual Meeting this week.

Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week